Towards Drug Safety Surveillance and Pharmacovigilance: Current Progress in Detecting Medication and Adverse Drug Events from Electronic Health Records
Department of Quantitative Health Sciences; Department of Radiology; Department of Medicine
Artificial Intelligence and Robotics | Health Information Technology | Health Services Administration | Health Services Research
Large-scale drug safety surveillance and pharmacovigilance are key components of effective drug regulation systems, clinical practice, and public health programs. Although the efficacy and safety of a drug must be demonstrated in a series of clinical trials prior to approval, many adverse drug events (ADEs) are detected only after a drug has been marketed when it is used by a larger and more diverse population than during clinical trials. Adverse drug events discovered after a drug is in broad use can be a significant cause of morbidity and mortality. Thus, effective and accurate post-market drug surveillance is in urgent demand for the protection of public health and the reduction of healthcare expenditures due to ADE-related hospital complications.
DOI of Published Version
Drug Saf. 2019 Jan;42(1):95-97. doi: 10.1007/s40264-018-0766-8. Link to article on publisher's site
Liu, Feifan; Jagannatha, Abhyuday; and Yu, Hong, "Towards Drug Safety Surveillance and Pharmacovigilance: Current Progress in Detecting Medication and Adverse Drug Events from Electronic Health Records" (2019). Population and Quantitative Health Sciences Publications. 1254.